Statute Details
- Title: Medicines (Medical Advertisements) Regulations
- Act Code: MA1975-RG2
- Legislative Type: Subsidiary legislation (sl)
- Authorising Act: Medicines Act (Chapter 176, Sections 52 and 74)
- Citation / Regulation Number: Rg 2
- Gazette / Original Citation: G.N. No. S 289/1977
- Revised Edition: 2000 RevEd (31 January 2000)
- Status: Current version as at 27 March 2026
- Key Provisions: Regulation 3 (permit requirement), Regulation 4 (application), Regulation 5 (validity), Regulation 6 (terms and conditions), Regulation 7 (refusal/suspension/revocation and appeal), Regulation 8 (printer/publisher duty), Regulation 10–11 (exceptions), Regulation 12 (permit number display), Regulation 13 (alterations/amendments), Regulation 13A (transfer of permit), Regulation 14 (fees), Regulation 15 (penalty)
- Schedule: Fees
What Is This Legislation About?
The Medicines (Medical Advertisements) Regulations (“the Regulations”) create a licensing and compliance framework for how medicinal products may be advertised in Singapore. In plain terms, they require most “medical advertisements” and “sales promotions” for medicinal products to be approved by the licensing authority before they are issued or promoted to the public.
The Regulations sit alongside the Medicines Act and are designed to manage public health risk. Advertising can influence prescribing and consumer behaviour, and misleading or unapproved promotional content may lead to inappropriate use of medicines. By requiring permits, controlling the content through conditions, and imposing duties on printers and publishers, the Regulations aim to ensure that promotional material is reviewed and controlled before it reaches its audience.
Practically, the Regulations are most relevant to pharmaceutical manufacturers, importers, distributors, marketing agencies, media publishers, and any party involved in producing or disseminating promotional content. They also matter to legal advisers because non-compliance can trigger criminal liability, including fines and imprisonment.
What Are the Key Provisions?
1) Permit requirement for medical advertisements and sales promotions (Regulation 3)
Regulation 3 is the core rule: except as provided in the Regulations, no person shall issue (or cause to be issued) any “medical advertisement” or conduct any “sales promotion” without first obtaining a permit from the licensing authority. This is a strict pre-approval model—permission is required before publication, distribution, or promotion.
“Sales promotion” is defined broadly to include sales campaigns (including door-to-door sales and price discounts), exhibitions, competitions, and other activities intended to introduce, publicise, or raise the profile, awareness, or visibility of the medicinal product. This means that promotional activity beyond traditional print or online ads—such as events, contests, and discount-driven campaigns—may still fall within the permit regime.
2) Application and renewal (Regulation 4) and validity (Regulation 5)
An application for a permit (or to renew one) must be made in the form required by the licensing authority. Once granted, a permit is valid for one year from the date it is granted unless revoked earlier. For practitioners, this one-year validity period is important for campaign planning, especially for multi-month marketing cycles and recurring promotional schedules.
3) Discretionary conditions and control (Regulation 6)
Even after a permit is granted, the licensing authority may impose terms and conditions. These conditions can be central to compliance: they may govern wording, claims, presentation, required disclaimers, or other content controls. A permit holder must therefore treat the permit not as a mere administrative formality but as a binding instrument that shapes what can be published.
4) Refusal, suspension, revocation, and appeal (Regulation 7)
Regulation 7 provides that the licensing authority may refuse to grant a permit, or suspend or revoke an existing permit, and may do so without assigning any reason. This is significant: the absence of a duty to give reasons can affect how parties assess risk and respond strategically.
Any person aggrieved by the refusal, suspension, or revocation may appeal to the Minister, whose decision is final. From a legal practice perspective, this finality means that once the Minister decides, there is no further appeal under these Regulations. Advisers should therefore ensure that applications and supporting materials are robust at the outset, because the opportunity to contest outcomes is limited and procedurally constrained.
5) Duty of printer or publisher (Regulation 8)
Regulation 8 imposes a compliance duty on those who print or publish medical advertisements. No person shall print or publish (or cause to be printed or published) any medical advertisement that is not a sales promotion unless they have ascertained that a permit has been granted for that advertisement.
This provision is particularly relevant to publishers, printing houses, and media platforms. It creates a gatekeeping obligation: even if a marketer claims it has a permit, the printer/publisher must verify. For counsel, this suggests that contractual arrangements with vendors should include permit verification processes and documentary evidence.
6) Exceptions: trade/business targeting and non-public access (Regulation 10)
Regulation 10 provides that Regulation 3 does not apply to a medical advertisement that is directed exclusively at a person who may lawfully sell or supply medicinal products in the course of that person’s trade, business, or profession, and is not accessible to the general public. In other words, professional-only communications may be outside the permit requirement if they are properly restricted.
7) Exceptions: reference advertisements and trade advertisements; public authority carve-outs (Regulation 11)
Regulation 11 excludes certain categories from the Regulations. The Regulations do not apply to:
- a “reference advertisement” (a brief description of a medicinal product, its use, and any contraindications or warnings, appearing without charge in a publication mainly consisting of such advertisements, and sent/delivered to practitioners or pharmacists by a person not involved in the sale or dealings in that medicinal product as a manufacturer, supplier, retailer, importer or exporter);
- a “trade advertisement” (e.g., in a catalogue or price list for wholesale supply, without recommendations relating to use other than as part of the medicinal product name or therapeutic classification headings);
- any medical advertisement issued or published by a public authority; and
- any medical advertisement issued or published by a person authorised by the Minister.
These exceptions are narrow and definition-driven. Practitioners should carefully map the proposed content and distribution channel to the statutory definitions to avoid inadvertently falling within the permit requirement.
8) Permit number display (Regulation 12)
Any person who issues or publishes a medical advertisement (including conducting a sales promotion) must ensure that the permit number is displayed on, or on material accompanying, the advertisement, in accordance with terms and conditions specified in the permit. This is a transparency requirement and a practical compliance checkpoint for marketing teams and designers.
9) Alterations and amendments (Regulation 13)
A person must not alter or amend the contents of a medical advertisement for which a permit has been granted unless:
- they apply (in the form required) to amend the permit to reflect the alteration/amendment; and
- the licensing authority approves the application.
This means that even minor changes—such as adjusting claims, modifying dosage statements, changing images, or updating promotional copy—may require an amendment approval. Counsel should advise clients to treat “content change” as a legal trigger, not merely a marketing workflow issue.
10) Transfer of permit (Regulation 13A)
A permit cannot be transferred unless the permit holder applies (in the required form) to transfer the permit to another person and the licensing authority approves the application. This matters in corporate restructuring, acquisitions, and outsourcing arrangements where marketing rights or responsibilities shift between entities.
11) Fees and no refunds (Regulation 14 and Schedule)
Regulation 14 sets out that fees are payable for applications for permits, permits/renewals, amendments, and transfers, with amounts specified in the Schedule. No refund is made for any fee paid. For budgeting and procurement, this no-refund rule is important: unsuccessful applications or amendments may not be recoverable.
12) Penalty for contravention (Regulation 15)
Any person who contravenes or fails to comply with Regulations 3, 8, 12, or 13 commits an offence. On conviction, liability includes a fine not exceeding S$5,000 or imprisonment for up to 12 months, or both. This criminal exposure underscores that compliance is not optional and that enforcement can target multiple actors across the advertising chain.
How Is This Legislation Structured?
The Regulations are structured as follows:
- Regulation 1: Citation.
- Regulation 2: Definitions, including “medical advertisement” and “sales promotion”, and a “grant” definition that includes renewal.
- Regulations 3–7: The permit system—requirement, application, validity, conditions, and enforcement through refusal/suspension/revocation plus appeal.
- Regulations 8–13A: Compliance duties and operational controls—printer/publisher duty, exceptions, permit number display, alteration restrictions, and transfer of permits.
- Regulation 14: Fees (with amounts in the Schedule).
- Regulation 15: Penalty provisions.
- The Schedule: Fees payable for the various application and administrative actions.
Who Does This Legislation Apply To?
The Regulations apply to “any person” involved in issuing, publishing, printing, or conducting sales promotions of medicinal products, subject to the specific exceptions. This includes pharmaceutical companies and their marketing arms, as well as third parties such as advertising agencies, printers, publishers, and media platforms that may be asked to print or publish promotional material.
Importantly, liability is not limited to the permit applicant. Regulation 8 creates a duty for printers and publishers to ascertain that a permit exists (for non-sales-promotion medical advertisements). Regulation 12 and Regulation 13 impose obligations on those who issue/publish and those who alter content. Accordingly, compliance should be implemented across the entire workflow—from regulatory submissions to creative production and final publication.
Why Is This Legislation Important?
For practitioners, the Regulations are important because they translate regulatory oversight into practical advertising controls. The permit requirement and the one-year validity period create a compliance calendar. The conditions attached to permits and the prohibition on altering content without amendment approval mean that marketing teams must coordinate closely with regulatory counsel.
The enforcement architecture is also meaningful. The licensing authority can refuse, suspend, or revoke permits without giving reasons, and the Minister’s decision on appeal is final. This places a premium on the quality of initial submissions and on maintaining strict adherence to permit conditions and permit-number display requirements.
Finally, the criminal penalty provision—covering contraventions of Regulation 3 (permit requirement), Regulation 8 (printer/publisher duty), Regulation 12 (permit number display), and Regulation 13 (alterations)—means that non-compliance can lead to serious consequences. In practice, this encourages robust internal controls, vendor due diligence, and documented verification steps before publication.
Related Legislation
- Medicines Act (Chapter 176): In particular, Sections 52 and 74 (authorising the Regulations), and references to exclusions from “medical advertisement” in Section 51.
Source Documents
This article provides an overview of the Medicines (Medical Advertisements) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.